Skip to content

Study · Randomized controlled trial · n = 50 · 2004

6 results

The effects of calcitonin on acute bone loss after pertrochanteric fractures. A prospective, randomised trial.

Karachalios T, Lyritis GP, Kaloudis J, Roidis N, Katsiri M

The Journal of bone and joint surgery. British volume1 Apr 2004Cited by 19 (Europe PMC)

PMID15125121 (opens in a new tab)DOI10.1302/0301-620x.86b3.14300 (opens in a new tab)PepBankPUB-15125121
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with pertrochanteric fractures, calcitonin increased total alkaline phosphatase versus placebo on the 15th day after injury.

    In plain wordsIn women with hip fractures, calcitonin increased total alkaline phosphatase more than placebo after injury.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseTotal alkaline phosphatase
    Study

    n = 50

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 IU daily · intranasal · three monthsAs given in this study (human).

    Source sentences

    Summary
    Patients in group A showed a significantly higher level of total alkaline phosphatase and osteocalcin on the 15th day after injury and a significantly higher level of bone alkaline phosphatase on the 90th day after surgery.
    1 context sentence
    Summary · context
    Fifty women aged between 70 and 80 years who had a pertrochanteric fracture of the hip were randomly allocated to group A (200 IU of nasal salmon calcitonin daily for three months) or group B (placebo).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with pertrochanteric fractures, calcitonin increased osteocalcin versus placebo on the 15th day after injury.

    In plain wordsIn women with hip fractures, calcitonin increased osteocalcin more than placebo after injury.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseOsteocalcin
    Study

    n = 50

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 IU daily · intranasal · three monthsAs given in this study (human).

    Source sentences

    Summary
    Patients in group A showed a significantly higher level of total alkaline phosphatase and osteocalcin on the 15th day after injury and a significantly higher level of bone alkaline phosphatase on the 90th day after surgery.
    1 context sentence
    Summary · context
    Fifty women aged between 70 and 80 years who had a pertrochanteric fracture of the hip were randomly allocated to group A (200 IU of nasal salmon calcitonin daily for three months) or group B (placebo).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with pertrochanteric fractures, calcitonin increased bone alkaline phosphatase versus placebo on the 90th day after surgery.

    In plain wordsIn women with hip fractures, calcitonin increased bone alkaline phosphatase more than placebo after surgery.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseBone alkaline phosphatase
    Study

    n = 50

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 IU daily · intranasal · three monthsAs given in this study (human).

    Source sentences

    Summary
    Patients in group A showed a significantly higher level of total alkaline phosphatase and osteocalcin on the 15th day after injury and a significantly higher level of bone alkaline phosphatase on the 90th day after surgery.
    1 context sentence
    Summary · context
    Fifty women aged between 70 and 80 years who had a pertrochanteric fracture of the hip were randomly allocated to group A (200 IU of nasal salmon calcitonin daily for three months) or group B (placebo).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women with pertrochanteric fractures, calcitonin lowered urinary C-telopeptide versus placebo on the 15th, 45th and 90th days after injury.

    In plain wordsIn women with hip fractures, calcitonin lowered urinary C-telopeptide more than placebo after injury.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseUrinary C-telopeptide
    Study

    n = 50

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 IU daily · intranasal · three monthsAs given in this study (human).

    Source sentences

    Summary
    These patients also had significantly lower levels of urinary C-telopeptide (CrossLaps) on the 15th, 45th and 90th days after injury and lower levels of urinary hydroxyproline on the 15th and 45th days after injury.
    1 context sentence
    Summary · context
    Fifty women aged between 70 and 80 years who had a pertrochanteric fracture of the hip were randomly allocated to group A (200 IU of nasal salmon calcitonin daily for three months) or group B (placebo).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In women with pertrochanteric fractures, calcitonin lowered urinary hydroxyproline versus placebo on the 15th and 45th days after injury.

    In plain wordsIn women with hip fractures, calcitonin lowered urinary hydroxyproline more than placebo after injury.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseUrinary hydroxyproline
    Study

    n = 50

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 IU daily · intranasal · three monthsAs given in this study (human).

    Source sentences

    Summary
    These patients also had significantly lower levels of urinary C-telopeptide (CrossLaps) on the 15th, 45th and 90th days after injury and lower levels of urinary hydroxyproline on the 15th and 45th days after injury.
    1 context sentence
    Summary · context
    Fifty women aged between 70 and 80 years who had a pertrochanteric fracture of the hip were randomly allocated to group A (200 IU of nasal salmon calcitonin daily for three months) or group B (placebo).
  6. 06HumanRandomized controlled trialEfficacy outcome

    In women with pertrochanteric fractures, BMD was significantly higher with calcitonin than placebo at three months and one year, except at the greater trochanter.

    In plain wordsIn women with hip fractures, bone density was higher with calcitonin than placebo, except at the greater trochanter.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseBMD at recorded sites except greater trochanter
    Study

    n = 50

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 IU daily · intranasal · three monthsAs given in this study (human).

    Source sentences

    Summary
    Patients in group A had significantly higher bone mineral density at all recorded sites except the greater trochanter at three months and one year after operation.
    1 context sentence
    Summary · context
    Fifty women aged between 70 and 80 years who had a pertrochanteric fracture of the hip were randomly allocated to group A (200 IU of nasal salmon calcitonin daily for three months) or group B (placebo).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.